Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020

Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020

This cross-sectional study examines the proportion of Medicaid prescription and spending on drugs marketed in the United States without Food and Drug Administration approval.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of internal medicine (1960) 2022-03, Vol.182 (3), p.342-345
Hauptverfasser: Gunter, Simon J, Kesselheim, Aaron S, Rome, Benjamin N
Format: Artikel
Sprache:eng
Schlagworte:
Drug Approval
Drug Costs
Drugs, Generic
FDA approval
Health care expenditures
Health Care Policy and Law
Humans
Letters
Medicaid
Online First
Pharmaceutical Preparations
Prescription drugs
Research Letter
United States
United States Food and Drug Administration
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This cross-sectional study examines the proportion of Medicaid prescription and spending on drugs marketed in the United States without Food and Drug Administration approval.
ISSN:2168-6106
2168-6114
DOI:10.1001/jamainternmed.2021.7614